Niezgoda MD FACHM FACEP FAPWCA as Directorof the Company’s Medical Advisory Board Dr

Niezgoda, MD, FACHM, FACEP, FAPWCA as Directorof the Company’s Medical Advisory Board Dr. Jeffrey Niezgoda is a leading wound management physician and the MedicalDirector of the Centers for Comprehensive Wound Care and Hyperbaric OxygenTherapy in Milwaukee, Wisconsin. He also serves as the President and ChiefOperating Officer of Hyperbaric & Wound Care Associates, a medical specialtygroup serving Southeastern Wisconsin and Northern Illinois, and as thePresident of the American College of Hyperbaric Medicine Dr. Wake Pharm US Announces Appointment of Jeffrey A Niezgoda, M.D.

See the company’s SEC filings,and in particular, the risk factors described in the company’s Annual Reporton Form 10-K and its most recent Quarterly Report on Form 10-Q. Sangamoassumes no obligation to update the forward-looking information contained inthis press release.SOURCESangamo BioSciences, Inc.Elizabeth Wolffe, Ph.D., of Sangamo BioSciences, Inc., +1-510-970-6000, Ext.271, . Stratos and Modern Security Solutions to Jointly Market AFIANT SatelliteNetwork Video Management System–Agreement establishes Modern Security Solutions as Stratos ECO-Partnerfor remote security services–BETHESDA, MD, June 29 /PRNewswire/ – Stratos Global Corporation, the leadingglobal provider of advanced mobile and fixed-site remote communicationssolutions, today announced it has signed an agreement with Modern SecuritySolutions Ltd. We advise policy makers, design innovative solutions, integratesystems and – most of all – deliver to the public.Serco supports governments, agencies and companies who seek a trusted partnerwith a solid track record of providing assured service excellence. On 19 June 2009, Candover announced that CPL had agreed to sell Wood Mackenzieto Charterhouse Capital Partners for an enterprise value of £553 million. It hasestablished a reduced risk business model primarily upon identifying new usesfor established drugs and exploiting its unique position within Japanese,European and North American pharmaceutical markets by acquiring compoundsfrom, and bringing compounds into, Japan.For further information about Sosei, please visit http:// VecturaVectura Group plc is a product-focused Group that develops inhaledtherapies principally for the treatment of respiratory diseases.

COPD is currently the fourth most common cause ofdeath and by 2030 is predicted to become the third most common cause of deathand the fourth most important disability causing illness. Novartis is responsible for developing andcommercializing NVA237 both as a monotherapy and in combination withindacaterol, its once daily, long-acting beta-2 agonist, as QVA149.Under the terms of the agreement, Sosei and Vectura to date have eachreceived $15 million and will each receive up to $172.5 million for achievingpre-agreed clinical, regulatory and commercialisation targets for both themonotherapy and combination product These potential milestones total up to$375 million. A number ofsecondary endpoints will also be evaluated.NVA237 was licensed to Novartis in April 2005 by Sosei and itsco-development partner Vectura. Eachpatient will be randomised to receive a once-daily dose of placebo,tiotropium bromide or 50microg of NVA237 for a 52-week period. NVA237 is a dry powder formulation for oral inhalation ofglycopyrronium bromide, a LAMA with a rapid onset of activity. For latest earnings estimates made by Toyo Keizai, pleasedouble click on 8887.TK1..

For latest earnings estimates made by Toyo Keizai, pleasedouble click on 8887.TK1.. For latest earnings estimates made by Toyo Keizai, pleasedouble click on 6278.TK1.. For latest earnings estimates made by Toyo Keizai, pleasedouble click on 6278.TK1.. STOCKHOLM, June 29 (Reuters) – The following stocks may beaffected by newspaper reports and other factors on Monday: SEVAN MARINE (SEVAN.OL) The Norwegian offshore services group said it was raising968 million Norwegian crowns ($150 million) in privateplacement. In addition, the pharmacodynamic assay used in this studydemonstrated the ability of EVT 401 to block ATP-stimulated IL-1beta release inwhole blood samples taken from subjects, thereby proving “on target” activity atwell tolerated oral doses.In Rheumatoid Arthritis, the first potential indication for EVT 401, there is asignificant need for new oral therapies. A total of 96healthy male volunteers received single oral ascending doses of the compound asa suspension or capsule.The compound was very safe and well tolerated and there were no serious adverseevents or withdrawals.